Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment ( YUSHIMA Study)
International Journal of Urology · 2025
DOI: 10.1111/iju.70136 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Tomoki Kimura und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms, Renal Insufficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate the impact of renal impairment (RI) on the efficacy of first‐line chemotherapy in patients with locally advanced or metastatic upper tract urothelial carcinoma (la/mUTUC).
Methods
This multicenter retrospective study evaluated 300 patients with la/mUTUC who received GEM/CDDP or GEM/CBDCA as first‐line chemotherapy. RI was defined as eGFR < 45 mL/min/1.73 m 2 and used to categorize patients into RI and without‐RI groups. Objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS) were analyzed. Multivariable Cox proportional hazard analysis was conducted to assess risk factors for PFS and OS. In the RI group, oncologic outcomes were compared between GEM/CDDP and GEM/CBDCA.
Results
Overall, 130 patients (43%) had RI, and 170 (57%) did not. During a median follow‐up of 32 months, 188 patients (63%) died: 74 patients (56%) in the RI group and 114 (67%) in the without‐RI group. Among 288 evaluable patients, the ORR was 34% in the RI group and 45% in the without‐RI group ( p = 0.072). The median PFS of the RI and without‐RI groups was 5.6 and 4.8 months, respectively ( p = 0.322), and the median OS was 16.9 and 14.5 months, respectively ( p = 0.074). Among the RI group, no significant differences were observed between GEM/CDDP and GEM/CBDCA in PFS (6.4 vs. 4.2 months, p = 0.113) or OS (21.4 vs. 15.2 months, p = 0.142).
Conclusions
In la/mUTUC, oncologic outcomes were comparable between patients with and without RI. In the RI group, responses to GEM/CDDP and GEM/CBDCA did not differ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Urology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
- Department of Urology, Soka Municipal Hospital, Saitama, Japan.
- Department of Urology, JA Toride Medical Hospital, Ibaraki, Japan.
- Department of Urology, Saitama Red Cross Hospital, Saitama, Japan.
- Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
ORCID-Profile: Tomoki Kimura, Motohiro Fujiwara, Keita Izumi, Masahiro Toide, Ryoji Takazawa, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii
Zitieren
APA
Kimura, T., Fujiwara, M., Maezawa, Y., Ishihara, K., Inoue, N., Tanabe, K., Izumi, K., Toide, M., Yamamoto, T., Uehara, S., Araki, S., Inoue, M., Takazawa, R., Numao, N., Ohtsuka, Y., Waseda, Y., Tanaka, H., Yoshida, S., & Fujii, Y. (2025). Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment ( YUSHIMA Study). International Journal of Urology. https://doi.org/10.1111/iju.70136
Vancouver
Kimura T, Fujiwara M, Maezawa Y, Ishihara K, Inoue N, Tanabe K, et al. Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment ( YUSHIMA Study). International Journal of Urology. 2025. doi:10.1111/iju.70136
BibTeX
@article{Kimura2025,
author = {Kimura, Tomoki and Fujiwara, Motohiro and Maezawa, Yuya and Ishihara, Kensaku and Inoue, Naoki and Tanabe, Kenji and Izumi, Keita and Toide, Masahiro and Yamamoto, Takanobu and Uehara, Sho and Araki, Saori and Inoue, Masaharu and Takazawa, Ryoji and Numao, Noboru and Ohtsuka, Yukihiro and Waseda, Yuma and Tanaka, Hajime and Yoshida, Soichiro and Fujii, Yasuhisa},
title = {Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment ( YUSHIMA Study)},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70136}
}
EUVIMED